Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F3VN
|
|||
| Drug Name |
Sulfamoylamide derivative 1
|
|||
| Synonyms |
PMID29473428-Compound-61
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
BRISTOL-MYERS SQUIBB COMPANY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H37ClFN5O5S
|
|||
| Canonical SMILES |
CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)OCC(=O)NS(=O)(=O)N(C)C)NC(=O)NC3=C(C=C(C=C3)Cl)F
|
|||
| InChI |
1S/C27H37ClFN5O5S/c1-18(2)16-34(20-8-6-5-7-9-20)25-13-11-21(39-17-26(35)32-40(37,38)33(3)4)15-24(25)31-27(36)30-23-12-10-19(28)14-22(23)29/h10-15,18,20H,5-9,16-17H2,1-4H3,(H,32,35)(H2,30,31,36)
|
|||
| InChIKey |
GXQLSHAYKCFGCU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target's Patent Info | [1] | |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation | ||||
| L-kynurenine degradation | ||||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
| NAD de novo biosynthesis | ||||
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| African trypanosomiasis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Tryptophan Metabolism | |||
| Reactome | Tryptophan catabolism | |||
| WikiPathways | Tryptophan metabolism | |||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.